Furin targeted drug delivery for treatment of Rhabdomyosarcoma in a mouse model

PLoS ONE

Volumn 5, Issue 5, 2010, Pages

  Hajdin, Katarina ^a   D'Alessandro, Valentina ^a   Niggli, Felix K ^a   Schäfer, Beat W ^a   Bernasconi, Michele ^a  

^a UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; FURIN; MEMBRANE PROTEIN; PROPROTEIN CONVERTASE 7; SERINE PROTEINASE; UNCLASSIFIED DRUG;

AFFINITY CHROMATOGRAPHY; AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING SITE; BIOPANNING; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; GENE EXPRESSION PROFILING; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MEMBRANE BINDING; MOLECULAR LIBRARY; MOUSE; NONHUMAN; PHAGE DISPLAY; PROTEIN BINDING; RHABDOMYOSARCOMA;

AMINO ACID MOTIFS; AMINO ACID SEQUENCE; ANIMALS; CELL LINE, TUMOR; CELL MEMBRANE; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; DOXORUBICIN; DRUG DELIVERY SYSTEMS; FLUORESCEIN-5-ISOTHIOCYANATE; FURIN; GOLGI APPARATUS; HUMANS; MICE; MOLECULAR SEQUENCE DATA; PEPTIDE LIBRARY; PEPTIDES; PROTEIN BINDING; RECEPTORS, CELL SURFACE; REPRODUCIBILITY OF RESULTS; RHABDOMYOSARCOMA; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS;

EID: 77956287381     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0010445     Document Type: Article

References (58)

1. De Giovanni C, Landuzzi L, Nicoletti G, Lollini PL, Nanni P (2009) Molecular and cellular biology of rhabdomyosarcoma. Future Oncol 5: 1449-1475.
2. Breitfeld PP, Meyer WH (2005) Rhabdomyosarcoma: new windows of opportunity. Oncologist 10: 518-527.
3. Adams GP, Weiner LM (2005) Monoclonal antibody therapy of cancer. Nat Biotechnol 23: 1147-1157.
4. Levene AP, Singh G, Palmieri C (2005) Therapeutic monoclonal antibodies in oncology. J R Soc Med 98: 146-152.
5. Cortez-Retamozo V, Backmann N, Senter PD, Wernery U, De Baetselier P, et al. (2004) Efficient cancer therapy with a nanobody-based conjugate. Cancer Res 64: 2853-2857.
6. Stern M, Herrmann R (2005) Overview of monoclonal antibodies in cancer therapy: present and promise. Crit Rev Oncol Hematol 54: 11-29.
7. Aina OH, Sroka TC, Chen ML, Lam KS (2002) Therapeutic cancer targeting peptides. Biopolymers 66: 184-199.
8. Enback J, Laakkonen P (2007) Tumour-homing peptides: tools for targeting, imaging and destruction. Biochem Soc Trans 35: 780-783.
9. Aina O, Liu R, Sutcliffe J, Marik J, Pan C-X, et al. (2007) From Combinatorial Chemistry to Cancer-Targeting Peptides. Molecular pharmaceutics.
10. Ruoslahti E (2004) Vascular zip codes in angiogenesis and metastasis. Biochem Soc Trans 32: 397-402.
11. Zurita AJ, Arap W, Pasqualini R (2003) Mapping tumor vascular diversity by screening phage display libraries. J Control Release 91: 183-186.
12. Bergeron F, Leduc R, Day R (2000) Subtilase-like pro-protein convertases: from molecular specificity to therapeutic applications. J Mol Endocrinol 24: 1-22.
13. Seidah NG, Chretien M (1999) Proprotein and prohormone convertases: a family of subtilases generating diverse bioactive polypeptides. Brain Res 848: 45-62.
14. Nakayama K (1997) Furin: a mammalian subtilisin/Kex2p-like endoprotease involved in processing of a wide variety of precursor proteins. Biochem J 327 (Pt3): 625-635.
15. Thomas G (2002) Furin at the cutting edge: from protein traffic to embryogenesis and disease. Nat Rev Mol Cell Biol 3: 753-766.
16. Khatib AM, Siegfried G, Chretien M, Metrakos P, Seidah NG (2002) Proprotein convertases in tumor progression and malignancy: novel targets in cancer therapy. Am J Pathol 160: 1921-1935.
17. Bassi DE, Fu J, Lopez de Cicco R, Klein-Szanto AJ (2005) Proprotein convertases: "master switches" in the regulation of tumor growth and progression. Mol Carcinog 44: 151-161.
18. Bassi DE, Mahloogi H, Al-Saleem L, Lopez De Cicco R, Ridge JA, et al. (2001) Elevated furin expression in aggressive human head and neck tumors and tumor cell lines. Mol Carcinog 31: 224-232.
19. Siegfried G, Basak A, Cromlish JA, Benjannet S, Marcinkiewicz J, et al. (2003) The secretory proprotein convertases furin, PC5, and PC7 activate VEGF-C to induce tumorigenesis. J Clin Invest 111: 1723-1732.
20. McColl BK, Paavonen K, Karnezis T, Harris NC, Davydova N, et al. (2007) Proprotein convertases promote processing of VEGF-D, a critical step for binding the angiogenic receptor VEGFR-2. Faseb J 21: 1088-1098.
21. Dubois CM, Blanchette F, Laprise MH, Leduc R, Grondin F, et al. (2001) Evidence that furin is an authentic transforming growth factor-beta1-converting enzyme. Am J Pathol 158: 305-316.
22. Khatib AM, Siegfried G, Prat A, Luis J, Chretien M, et al. (2001) Inhibition of proprotein convertases is associated with loss of growth and tumorigenicity of HT-29 human colon carcinoma cells: importance of insulin-like growth factor-1 (IGF-1) receptor processing in IGF-1-mediated functions. J Biol Chem 276: 30686-30693.
23. Nelsen SM, Christian JL (2009) Site-specific cleavage of BMP4 by furin, PC6 and PC7. The Journal of biological chemistry.
24. Stawowy P, Kallisch H, Kilimnik A, Margeta C, Seidah NG, et al. (2004) Proprotein convertases regulate insulin-like growth factor 1-induced membranetype 1 matrix metalloproteinase in VSMCs via endoproteolytic activation of the insulin-like growth factor-1 receptor. Biochem Biophys Res Commun 321: 531-538.
25. Srour N, Lebel A, McMahon S, Fournier I, Fugere M, et al. (2003) TACE/ ADAM-17 maturation and activation of sheddase activity require proprotein convertase activity. FEBS Lett 554: 275-283.
26. Bergeron E, Basak A, Decroly E, Seidah NG (2003) Processing of alpha4 integrin by the proprotein convertases: histidine at position P6 regulates cleavage. Biochem J 373: 475-484.
27. Varshavsky A, Kessler O, Abramovitch S, Kigel B, Zaffryar S, et al. (2008) Semaphorin-3B is an angiogenesis inhibitor that is inactivated by furin-like proprotein convertases. Cancer Res 68: 6922-6931.
28. Scamuffa N, Siegfried G, Bontemps Y, Ma L, Basak A, et al. (2008) Selective inhibition of proprotein convertases represses the metastatic potential of human colorectal tumor cells. The Journal of clinical investigation 118: 352-363.
29. Fugere M, Day R (2005) Cutting back on pro-protein convertases: the latest approaches to pharmacological inhibition. Trends Pharmacol Sci 26: 294-301.
30. Bassi DE, Lopez De Cicco R, Mahloogi H, Zucker S, Thomas G, et al. (2001) Furin inhibition results in absent or decreased invasiveness and tumorigenicity of human cancer cells. Proc Natl Acad Sci USA 98: 10326-10331.
31. Lapierre M, Siegfried G, Scamuffa N, Bontemps Y, Calvo F, et al. (2007) Opposing Function of the Proprotein Convertases Furin and PACE4 on Breast Cancer Cells' Malignant Phenotypes: Role of Tissue Inhibitors of Metalloproteinase-1. Cancer Research 67: 9030-9034.
32. Sun X, Essalmani R, Seidah NG, Prat A (2009) The proprotein convertase PC5/6 is protective against intestinal tumorigenesis: in vivo mouse model. Mol Cancer 8: 73.
33. Chrétien M, Seidah NG, Basak A, Mbikay M (2008) Proprotein convertases as therapeutic targets. Expert opinion on therapeutic targets 12: 1289-1300.
34. Witt H, Hajdin K, Iljin K, Greiner O, Niggli FK, et al. (2009) Identification of a rhabdomyosarcoma targeting peptide by phage display with sequence similarities to the tumour lymphatic-homing peptide LyP-1. Int J Cancer 124: 2026-2032.
35. Mbikay M, Sirois F, Yao J, Seidah NG, Chretien M (1997) Comparative analysis of expression of the proprotein convertases furin, PACE4, PC1 and PC2 in human lung tumours. Br J Cancer 75: 1509-1514.
36. Komada M, Hatsuzawa K, Shibamoto S, Ito F, Nakayama K, et al. (1993) Proteolytic processing of the hepatocyte growth factor/scatter factor receptor by furin. FEBS Lett 328: 25-29.
37. Takahashi S, Nakagawa T, Kasai K, Banno T, Duguay SJ, et al. (1995) A second mutant allele of furin in the processing-incompetent cell line, LoVo. Evidence for involvement of the homo B domain in autocatalytic activation. J Biol Chem 270: 26565-26569.
38. Jean F, Stella K, Thomas L, Liu G, Xiang Y, et al. (1998) alpha1-Antitrypsin Portland, a bioengineered serpin highly selective for furin: application as an antipathogenic agent. Proc Natl Acad Sci USA 95: 7293-7298.
39. Laakkonen P, Porkka K, Hoffman JA, Ruoslahti E (2002) A tumor-homing peptide with a targeting specificity related to lymphatic vessels. Nat Med 8: 751-755.
40. Joyce JA, Laakkonen P, Bernasconi M, Bergers G, Ruoslahti E, et al. (2003) Stage-specific vascular markers revealed by phage display in a mouse model of pancreatic islet tumorigenesis. Cancer Cell 4: 393-403.
41. Teesalu T, Sugahara KN, Kotamraju VR, Ruoslahti E (2009) C-end rule peptides mediate neuropilin-1-dependent cell, vascular, and tissue penetration. Proc Natl Acad Sci USA 106: 16157-16162.
42. Sugahara KN, Teesalu T, Karmali PP, Kotamraju VR, Agemy L, et al. (2009) Tissue-penetrating delivery of compounds and nanoparticles into tumors. Cancer Cell 16: 510-520.
43. Futaki S (2006) Oligoarginine vectors for intracellular delivery: design and cellular-uptake mechanisms. Biopolymers 84: 241-249.
44. Nishimura S, Takahashi S, Kamikatahira H, Kuroki Y, Jaalouk DE, et al. (2008) Combinatorial targeting of the macropinocytotic pathway in Leukemia and lymphoma cells. The Journal of biological chemistry.
45. Decroly E, Wouters S, Di Bello C, Lazure C, Ruysschaert JM, et al. (1996) Identification of the paired basic convertases implicated in HIV gp160 processing based on in vitro assays and expression in CD4(+) cell lines. J Biol Chem 271: 30442-30450.
46. Kido H, Kamoshita K, Fukutomi A, Katunuma N (1993) Processing protease for gp160 human immunodeficiency virus type I envelope glycoprotein precursor in human T4+ lymphocytes. Purification and characterization. J Biol Chem 268: 13406-13413.
47. Laprise MH, Grondin F, Cayer P, McDonald PP, Dubois CM (2002) Furin gene (fur) regulation in differentiating human megakaryoblastic Dami cells: involvement of the proximal GATA recognition motif in the P1 promoter and impact on the maturation of furin substrates. Blood 100: 3578-3587.
48. Mercapide J, Lopez De Cicco R, Bassi DE, Castresana JS, Thomas G, et al. (2002) Inhibition of furin-mediated processing results in suppression of astrocytoma cell growth and invasiveness. Clin Cancer Res 8: 1740-1746.
49. Wick W, Wild-Bode C, Frank B, Weller M (2004) BCL-2-induced glioma cell invasiveness depends on furin-like proteases. J Neurochem 91: 1275-1283.
50. Oh P, Li Y, Yu J, Durr E, Krasinska KM, et al. (2004) Subtractive proteomic mapping of the endothelial surface in lung and solid tumours for tissue-specific therapy. Nature 429: 629-635.
51. Fogal V, Zhang L, Krajewski S, Ruoslahti E (2008) Mitochondrial/cell-surface protein p32/gC1qR as a molecular target in tumor cells and tumor stroma. Cancer Res 68: 7210-7218.
52. Christian S, Pilch J, Akerman ME, Porkka K, Laakkonen P, et al. (2003) Nucleolin expressed at the cell surface is a marker of endothelial cells in angiogenic blood vessels. J Cell Biol 163: 871-878.
53. Basak A, Khatib AM, Mohottalage D, Basak S, Kolajova M, et al. (2009) A novel enediynyl peptide inhibitor of furin that blocks processing of proPDGF-A, B and proVEGF-C. PLoS One 4: e7700.
54. Remacle AG, Gawlik K, Golubkov VS, Cadwell GW, Liddington RC, et al. (2010) Selective and potent furin inhibitors protect cells from anthrax without significant toxicity. International Journal of Biochemistry and Cell Biology.
55. Scholl FA, Betts DR, Niggli FK, Schafer BW (2000) Molecular features of a human rhabdomyosarcoma cell line with spontaneous metastatic progression. Br J Cancer 82: 1239-1245.
56. Bassi DE, Mahloogi H, Lopez De Cicco R, Klein-Szanto A (2003) Increased furin activity enhances the malignant phenotype of human head and neck cancer cells. Am J Pathol 162: 439-447.
57. Hoffman JA, Laakkonen P, Porkka K, Bernasconi M, Ruoslahti E (2004) In vivo and ex vivo selections using phage-displayed libraries. In: Clarkson T, Lowman H, eds. Phage Display: A Practical Approach. Oxford, U.K: Oxford University Press. pp 169-186.
58. Wachtel M, Dettling M, Koscielniak E, Stegmaier S, Treuner J, et al. (2004) Gene expression signatures identify rhabdomyosarcoma subtypes and detect a novel t(2;2)(q35;p23) translocation fusing PAX3 to NCOA1. Cancer Res 64: 5539-5545.